Elena Gatti, Lorenzo Marchetti, Giovanni B Frisoni, Annamaria Cattaneo, Samantha Galluzzi, Giovanni Sgrò, Serena Fiorito, Michela Pievani, Francesco Epifano, Salvatore Genovese, Andrea Geviti, Moira Marizzoni, Natale Salvatore Bonfiglio, Claudio Singh Solorzano
Journal: Nutrition journal 2024;23(1):135
PMID: 39482712
Subjective cognitive decline (SCD) refers to individuals’ perceived decline in brain function compared to their previous performance, without measurable (objective) brain deficits. This study aimed to investigate the effects of citrus peel extract on the brain function and biological characteristics of older adults experiencing SCD compared to a placebo. This was a 36-week, randomised, double-blind, parallel, mono-centric (conducted at a single research site), placebo-controlled clinical trial. A total of 80 participants were randomly assigned to receive citrus peel extract (n = 40) or placebo (n = 40). Results showed that both the citrus peel extract and placebo groups improved in the primary endpoint—the RBANS (Repeatable Battery for the Assessment of Neuropsychological Status, a tool that evaluates different cognitive domains)—as well as in other cognitive outcomes, including short- and long-term verbal memory and subjective memory, at the 36-week follow-up. Both groups also showed an increased inflammatory response. However, there were no significant differences between the two groups in cognitive outcomes, despite noticeable improvements in the citrus group. Authors concluded that their findings did not show a statistically significant difference in cognitive improvements between citrus peel extract and placebo groups. These findings are clinically relevant for healthcare practitioners, as they highlight the potential influence of placebo effects and individual expectations in interventions for early cognitive decline.
BACKGROUND
Developing interventions for older adults with subjective cognitive decline (SCD) has the potential to prevent dementia in this at-risk group. Preclinical models indicate that Citrus-derived phytochemicals could benefit cognition and inflammatory processes, but results from clinical trials are still preliminary. The aim of this study is to determine the effects of long-term supplementation with Citrus peel extract on cognitive performance and inflammation in individuals with SCD.
METHODS
Eighty participants were randomly assigned to active treatment (400 mg of Citrus peel extract containing 3.0 mg of naringenin and 0.1 mg of auraptene) or placebo at 1:1 ratio for 36 weeks. The primary endpoint was the change in the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) total score across the 36-week trial period. Other cognitive outcomes included tests and scales evaluating verbal memory, attention, executive and visuospatial functions, and memory concerns. The secondary endpoint was the change of interleukin-8 (IL-8) levels over the 36-week trial period in a subsample of 60 consecutive participants. An Intention-to-treat approach with generalized linear mixed models was used for data analysis.
RESULTS
The RBANS total score showed significant improvement in both Citrus peel extract and placebo groups at 36 weeks (p for time < .001, d = 0.36, p time x treatment = .910). Significant time effects were also found in cognitive domains of short- and long-term verbal memory (p < .001) and scales of subjective memory (p < .01), with no significant time x treatment interaction. The largest effect sizes were observed in verbal memory in the placebo group (d = 0.69 in short-term, and d = 0.78 in long-term verbal memory). Increased IL-8 levels were found at 36-week follow-up in both Citrus peel extract and placebo groups (p for time = .010, d = 0.21, p time x treatment = .772). Adverse events were balanced between groups.
CONCLUSIONS
In this randomized clinical trial, long-term Citrus peel extract supplementation did not show cognitive benefits over placebo in participants with SCD, possibly due to high placebo response. These findings might have specific implications for designing future nutraceutical trials in individuals experiencing SCD.
TRIAL REGISTRATION
The trial has been registered at the United States National Library of Medicine at the National Institutes of Health Registry of Clinical Trials under the code NCT04744922 on February 9th, 2021 ( https://www.
CLINICALTRIALS
gov/ct2/show/NCT04744922 ).
© 2024. The Author(s).
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.